Creating a live biobank for breast cancer patients
Official title: De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You
Run by Weill Medical College of Cornell University · NCT05134779 · Data updated 2026-11-12
This study is trying to create a collection of living tumor samples from breast cancer patients to better understand their cancer and find personalized treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | Women only |
| Enrollment | 400 (estimated) |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Locations | 2 sites (New York, New York and 1 other locations) |
| Status | Recruiting |
| Started | January 12, 2022 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | December 18, 2025 |
| Trial ID | NCT05134779 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with a historically proven diagnosis of breast cancer.
✕Probably not a fit
Patients with other cancers in addition to breast cancer will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on breast cancer patients to build a live tissue biobank of Patient Derived Tumor Organoids (PDOs). Samples will be collected at critical points during the disease course, including during surgery and at recurrence or metastasis. The goal is to understand the interactions between genes, the cancer environment, and the immune system to develop personalized therapies. Blood samples will also be collected to complement the tumor tissue data.
Why it matters
Potential benefit: If successful, this study could lead to more effective, personalized treatments for breast cancer patients.
How similar studies have gone: Other studies utilizing biobanks and patient-derived organoids have shown promise in advancing personalized cancer therapies, indicating a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients will historically proven BC are eligible to be on the study Exclusion Criteria: * Carriers of other cancers other than breast.
Where it's running
-
Brooklyn Methodist Hospital - NewYork Presbyterian
New York, New York, United States Recruiting -
New York Presbyterian Hospital - Queens
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Silvia Formenti, M.D. — Weill Medical College of Cornell University
- Study coordinator: Fabiana Gregucci, M.D.
- Email: fgr4002@med.cornell.edu
- Phone: 646-962-3110
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.